- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments
Telix Pharmaceuticals (ASX:TLX) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has entered into a strategic collaboration agreement with GenesisCare, the largest private provider of oncology services in Australia and Europe. As quoted in the press release: The …
Telix Pharmaceuticals (ASX:TLX) a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), today announced that it has entered into a strategic collaboration agreement with GenesisCare, the largest private provider of oncology services in Australia and Europe.
As quoted in the press release:
The agreement covers three major collaboration areas. Firstly, GenesisCare and Telix have established a preferred clinical provider relationship for running radiation oncology studies in Australia for the inclusion of patients into Telix’s global multi-centre trials in neuro-oncology and urologic oncology. Secondly, GenesisCare and Telix will partner to deliver compassionate use access to Telix’s glioblastoma therapy program across its extensive patient network. Finally, Telix and GenesisCare will jointly explore the commercial potential of Telix’s products in China.
Telix CEO Christian Behrenbruch stated, “GenesisCare is a unique organisation that has both patient access and geographic reach in radiation oncology. The kind of products that Telix is developing are a natural fit for the GenesisCare clinical network, both in terms of trials to support product development but also eventual product roll-out.”
GenesisCare CEO Dan Collins commented, “We see strategic collaborations with companies like Telix as a way to advance clinical trials and make proven new treatments available more quickly – ultimately to improve life outcomes for patients. Healthcare access for all is also very important to us, and the compassionate-use program as part of this agreement will be life-changing for the patients involved. We look forward to a long partnership with Telix.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.